These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

733 related articles for article (PubMed ID: 21892492)

  • 1. Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism.
    Shen J; He Q; Gao Y; Shi J; Li Y
    Nanoscale; 2011 Oct; 3(10):4314-22. PubMed ID: 21892492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
    Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
    Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled intracellular release of doxorubicin in multidrug-resistant cancer cells by tuning the shell-pore sizes of mesoporous silica nanoparticles.
    Gao Y; Chen Y; Ji X; He X; Yin Q; Zhang Z; Shi J; Li Y
    ACS Nano; 2011 Dec; 5(12):9788-98. PubMed ID: 22070571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
    Wang TX; Yang XH
    Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance.
    Wang J; Sun J; Chen Q; Gao Y; Li L; Li H; Leng D; Wang Y; Sun Y; Jing Y; Wang S; He Z
    Biomaterials; 2012 Oct; 33(28):6877-88. PubMed ID: 22770799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance.
    He Q; Gao Y; Zhang L; Zhang Z; Gao F; Ji X; Li Y; Shi J
    Biomaterials; 2011 Oct; 32(30):7711-20. PubMed ID: 21816467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming multidrug resistance of cancer cells by direct intranuclear drug delivery using TAT-conjugated mesoporous silica nanoparticles.
    Pan L; Liu J; He Q; Wang L; Shi J
    Biomaterials; 2013 Apr; 34(11):2719-30. PubMed ID: 23337327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
    Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
    J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redox-responsive nanoparticles from the single disulfide bond-bridged block copolymer as drug carriers for overcoming multidrug resistance in cancer cells.
    Wang YC; Wang F; Sun TM; Wang J
    Bioconjug Chem; 2011 Oct; 22(10):1939-45. PubMed ID: 21866903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells.
    Li R; Wu R; Zhao L; Wu M; Yang L; Zou H
    ACS Nano; 2010 Mar; 4(3):1399-408. PubMed ID: 20148593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multifunctional PLGA Nanobubbles as Theranostic Agents: Combining Doxorubicin and P-gp siRNA Co-Delivery Into Human Breast Cancer Cells and Ultrasound Cellular Imaging.
    Yang H; Deng L; Li T; Shen X; Yan J; Zuo L; Wu C; Liu Y
    J Biomed Nanotechnol; 2015 Dec; 11(12):2124-36. PubMed ID: 26510307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
    Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine.
    Jin J; Wang FP; Wei H; Liu G
    Cancer Chemother Pharmacol; 2005 Feb; 55(2):179-88. PubMed ID: 15378274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles.
    Fan J; Fang G; Wang X; Zeng F; Xiang Y; Wu S
    Nanotechnology; 2011 Nov; 22(45):455102. PubMed ID: 22019849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
    Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W
    J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance.
    Fan L; Li F; Zhang H; Wang Y; Cheng C; Li X; Gu CH; Yang Q; Wu H; Zhang S
    Biomaterials; 2010 Jul; 31(21):5634-42. PubMed ID: 20430433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
    Wong HL; Bendayan R; Rauth AM; Wu XY
    J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming multidrug resistance in human carcinoma cells by an antisense oligodeoxynucleotide--doxorubicin conjugate in vitro and in vivo.
    Ren Y; Wang Y; Zhang Y; Wei D
    Mol Pharm; 2008; 5(4):579-87. PubMed ID: 18461970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-delivery of doxorubicin and P-gp inhibitor by a reduction-sensitive liposome to overcome multidrug resistance, enhance anti-tumor efficiency and reduce toxicity.
    Tang J; Zhang L; Gao H; Liu Y; Zhang Q; Ran R; Zhang Z; He Q
    Drug Deliv; 2016 May; 23(4):1130-43. PubMed ID: 25491241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of doxorubicin resistance in P-glycoprotein overexpressing cells by hybrid cell-penetrating and drug-binding peptide.
    Zheng Z; Aojula H; Clarke D
    J Drug Target; 2010 Jul; 18(6):477-87. PubMed ID: 20088680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.